DAROLUTAMIDE

Search structure
Trade Names:
Synonyms:
Status: Approved (2019)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: L02BB06
UNII: X05U0N2RCO

Structure
InChI Key BLIJXOOIHRSQRB-PXYINDEMSA-N
Smile CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1
InChI
InChI=1S/C19H19ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11-12,27H,10H2,1-2H3,(H,22,28)(H,23,24)/t11-,12?/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C19H19ClN6O2
Molecular Weight 398.85
AlogP 2.67
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 6.0
Polar Surface Area 119.62
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 28.0

Pharmacology

Action Mechanism of Action Reference
ANTAGONIST Androgen Receptor antagonist
Primary Target
Androgen receptor
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Transferase
- - - - 3.453
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb
- - - - -24.56--7.23
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 4
- 26-1050 - 11-4231 -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 4 D009369 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 4 D064129 ClinicalTrials
Prostatic Neoplasms 4 D011471 ClinicalTrials
Prostatic Neoplasms 4 D011471 ClinicalTrials
Prostatic Neoplasms 4 D011471 ClinicalTrials
Granulosa Cell Tumor 2 D006106 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Salivary Gland Neoplasms 2 D012468 ClinicalTrials
Salivary Gland Neoplasms 2 D012468 ClinicalTrials

Cross References

Resources Reference
CAS NUMBER 1297538-32-9
ChEMBL CHEMBL4297185
DrugBank DB12941
FDA SRS X05U0N2RCO
Guide to Pharmacology 10439
PubChem 67171867
SureChEMBL SCHEMBL1814935
CONTENTS